ISIS reports data from ISIS-TTR Rx
Isis announced encouraging preliminary results from an investigator-sponsored study in patients with transthyretin amyloid-related cardiomyopathy. Measures of TTR amyloid cardiac disease indicated little to no cardiac disease progression after six months of dosing with ISIS-TTRRx. July 27, 2015